Rhythm Pharmaceuticals Inc
NASDAQ:RYTM
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
32.11
67.33
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one RYTM stock under the Base Case scenario is 55.247 USD. Compared to the current market price of 59.705 USD, Rhythm Pharmaceuticals Inc is Overvalued by 7%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Rhythm Pharmaceuticals Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for RYTM cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Rhythm Pharmaceuticals Inc
Balance Sheet Decomposition
Rhythm Pharmaceuticals Inc
Current Assets | 340.3m |
Cash & Short-Term Investments | 298.4m |
Receivables | 19.3m |
Other Current Assets | 22.6m |
Non-Current Assets | 23.2m |
PP&E | 4.4m |
Intangibles | 6.4m |
Other Non-Current Assets | 12.5m |
Current Liabilities | 97.6m |
Accounts Payable | 4.9m |
Accrued Liabilities | 54.8m |
Other Current Liabilities | 37.9m |
Non-Current Liabilities | 113.3m |
Long-Term Debt | 109.2m |
Other Non-Current Liabilities | 4m |
Earnings Waterfall
Rhythm Pharmaceuticals Inc
Revenue
|
112.5m
USD
|
Cost of Revenue
|
-12.8m
USD
|
Gross Profit
|
99.7m
USD
|
Operating Expenses
|
-365.2m
USD
|
Operating Income
|
-265.5m
USD
|
Other Expenses
|
4m
USD
|
Net Income
|
-261.5m
USD
|
Free Cash Flow Analysis
Rhythm Pharmaceuticals Inc
USD | |
Free Cash Flow | USD |
Rhythm Pharmaceuticals reported robust Q3 results with IMCIVREE revenue reaching $33.3 million, a 14% increase from the previous quarter. U.S. sales accounted for $23.3 million, up 8% sequentially, driven by rising patient reimbursements. International revenue hit $10 million—a 35% increase—reflecting expanding markets. Cash usage decreased to $22.6 million, and guidance for operating expenses was lowered to $245-$255 million. Looking ahead, the company plans to share Phase III data on hypothalamic obesity in early 2025. Additionally, the FDA review for expanding IMCIVREE's indication to children as young as two is expected by December 26, 2024, promising more patient engagement.
What is Earnings Call?
RYTM Profitability Score
Profitability Due Diligence
Rhythm Pharmaceuticals Inc's profitability score is 34/100. The higher the profitability score, the more profitable the company is.
Score
Rhythm Pharmaceuticals Inc's profitability score is 34/100. The higher the profitability score, the more profitable the company is.
RYTM Solvency Score
Solvency Due Diligence
Rhythm Pharmaceuticals Inc's solvency score is 64/100. The higher the solvency score, the more solvent the company is.
Score
Rhythm Pharmaceuticals Inc's solvency score is 64/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
RYTM Price Targets Summary
Rhythm Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for RYTM is 71.678 USD with a low forecast of 58.58 USD and a high forecast of 88.2 USD.
Dividends
Current shareholder yield for RYTM is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
RYTM Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing and commercializing peptide therapeutics for the treatment of gastrointestinal diseases and genetic deficiencies. The company is headquartered in Boston, Massachusetts and currently employs 140 full-time employees. The company went IPO on 2017-10-05. The firm is focused on developing treatment for genetic diseases of obesity, which are characterized by early-onset, severe obesity and an insatiable hunger (hyperphagia). The Company’s lead product candidate, IMCIVREE (setmelanotide), is a potent melanocortin-4 receptor (MC4R). IMCIVREE is developed for the treatment of rare genetic diseases of obesity. The company is focused on the melanocortin-4 receptor (MC4R) pathway, which is responsible for regulating weight and hunger. The company targets the MC4R pathway to develop therapeutics for rare genetic diseases of obesity, including proopiomelanocortin (POMC) deficiency obesity, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl syndrome (BBS), Alstrom syndrome, POMC or LEPR heterozygous deficiency obesity, Smith-Magenis syndrome, steroid receptor coactivator 1 (SRC1) deficiency obesity, MC4R deficiency obesity and SH2B adapter protein 1 (SH2B1) deficiency obesity.
Contact
IPO
Employees
Officers
The intrinsic value of one RYTM stock under the Base Case scenario is 55.247 USD.
Compared to the current market price of 59.705 USD, Rhythm Pharmaceuticals Inc is Overvalued by 7%.